Skip to main content
K

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 325 across all filing types
Latest filing 2024-12-30 Director's Dealing
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a change in share ownership by a director (Yang Kyung-hoon) of Komipharm. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2024-12-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details specific share transactions (purchases) made by a director/major shareholder (Yang Kyung-hoon) of Komipharm. This type of filing is classified as a 'Director's Dealing' (DIRS) as it reports personal share transactions by company insiders.
2024-12-27 Korean
[기재정정]반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for Komipharm, which is a comprehensive financial report covering the period from January 1, 2024, to June 30, 2024. It includes detailed financial statements, management discussion and analysis, and corporate governance information. Although it is labeled as a '정정신고' (Correction Report), it contains the full content of the interim report being corrected. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim/Quarterly Report (IR). H1 2024
2024-12-27 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to attend the 53rd Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of a corporate action (setting a record date). Given its nature as a regulatory notification regarding shareholder rights and meeting preparation, it fits best under the general regulatory filing category.
2024-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This is a standard regulatory filing in South Korea used to disclose insider trading activities (purchases/sales of shares by directors or major shareholders). Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2024-11-18 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report of Changes in Shareholding by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details specific share transactions (purchases) made by a company director (Park Yong-nam) of Komipharm. This type of filing is categorized as 'Director's Dealing' (DIRS) as it reports insider trading activities by company management.
2024-11-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.